Post-infusion recovery spans 1–2 weeks; temporary flu-like symptoms or mild fever occur in 10–15% of recipients. Kidney functional assessment begins at 6 weeks; meaningful decline stabilisation is typically evident by 12 weeks. Patients continue standard CKD management (blood-pressure control, proteinuria reduction, mineral-bone metabolism monitoring) throughout; no reduction in conventional medications is recommended without nephrologist consensus.
Trial databases document glomerular filtration rate (GFR) trajectories in CKD cohorts receiving placental or umbilical-cord MSCs. Representative phase II studies report GFR decline stabilisation or modest improvement (mean +3–8 mL/min/1.73m² over 12 months) in 45–60% of participants, versus continued decline in placebo arms. Proteinuria reduction (24-hour urine protein <50% baseline) occurs in 35–50% within 6 months. Histological fibrosis progression slows in kidney biopsy samples from responders. These outcomes remain investigational; no large pivotal trial has yet shaped clinical guidelines.
هل أنا مرشح؟ → · Chronic Kidney Disease: full overview → · تكلفة أمراض الكلى المزمنة → · Cost →
تم المراجعة الطبية بواسطة فريق التحرير StemCellAtlas مع Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) من عيادة الشريك Stem Plus (صوفيا)، وفقاً لـ ISSCR و FDA و EMA. Educational information, not medical advice; figures indicative.
طب تجديدي معتمد GMP في قلب الاتحاد الأوروبي — من 3,000 إلى 8,000 يورو، جزء بسيط من أسعار أمريكا أو ألمانيا. بروتوكولات مخصصة لمرضى من أكثر من 50 دولة.
مراجعة طبية مجانية